70.70 USD
▲-1.52+9.77%
盘后 64.28 -0.20%
2026-08-03
市值
$3.37B
市盈率
—
EPS
-2.18
股息率
—
52 周区间
9.63 – 69.40
成交量
695.95K
Beta
—
目标价
80.40
52W 低 9.6352W 高 69.40
价格走势
公司简介
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo...